D&O Disclosure Notices (Multiple)

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 28 February 2020
Date of last disclosure: 5 February 2020

Director or senior manager giving disclosure
Full name(s): Elizabeth Coutts
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Beneficial owner of shares
acquired pursuant to the Dividend
Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 1,165,649
Number held in class after acquisition or disposal: 1,180,936
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Custodial Services Limited

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 24 February 2020
Nature of transaction: Acquisition of 15,287 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$17,962.77
Number of financial products to which the transaction
related:
15,287
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -

The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 28 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 28 February 2020
Date of last disclosure: 5 February 2020

Director or senior manager giving disclosure
Full name(s): Alan Isaac
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Beneficial owner of shares
acquired pursuant to the Dividend
Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 131,564
Number held in class after acquisition or disposal: 133,289
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Alan Raymond Isaac, Andrew
John Dinsdale and Alasdair
Donald McBeth as trustees of
Isaac Family Trust

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and beneficial owner
of shares acquired pursuant to
the Dividend Reinvestment Plan
2019
For that relevant interest -
Number held in class before acquisition or disposal: 111,912
Number held in class after acquisition or disposal: 113,379
Current registered holder(s): New share issue

Registered holder(s) once transfers are registered: Alan Raymond Isaac

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 24 February 2020
Nature of transaction: Acquisition of 1,725 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$2,026.94
Number of financial products to which the transaction
related:
1,725
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No

Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 24 February 2020
Nature of transaction: Acquisition of 1,467 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan
2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$1,724.57
Number of financial products to which the transaction
related:
1,467
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest: Registered and beneficial owner
of shares
For that relevant interest -
Number held in class: 5,000
Current registered holder(s): Mary Isaac
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A

Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 28 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 28 February 2020
Date of last disclosure: 5 February 2020

Director or senior manager giving disclosure
Full name(s): Kerry Prendergast
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and beneficial owner
of shares acquired pursuant to
the Dividend Reinvestment Plan
2019
For that relevant interest -
Number held in class before acquisition or disposal: 303,477
Number held in class after acquisition or disposal: 307,457
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Kerry Prendergast

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 24 February 2020
Nature of transaction: Acquisition of 3,980 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$4,676.58
Number of financial products to which the transaction
related:
3,980
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -

The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 28 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 28 February 2020
Date of last disclosure: 5 February 2020

Director or senior manager giving disclosure
Full name(s): Sally Evans
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and beneficial owner
of shares acquired pursuant to
the Dividend Reinvestment Plan
2019
For that relevant interest -
Number held in class before acquisition or disposal: 39,641
Number held in class after acquisition or disposal: 40,300
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Sally Evans

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 24 February 2020
Nature of transaction: Acquisition of 659 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan
2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$774.98
Number of financial products to which the transaction
related:
659
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -
Type of derivative: N/A

Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 28 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 28 February 2020
Date of last disclosure: 5 February 2020

Director or senior manager giving disclosure
Full name(s): Gregory Tomlinson
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Gregory Tomlinson has the power
to control the exercise of a right to
vote attached to the product and
the power to control the
acquisition and disposal of the
product. These shares were
acquired pursuant to the Dividend
Reinvestment Plan 2019.
For that relevant interest -
Number held in class before acquisition or disposal: 13,950,283
Number held in class after acquisition or disposal: 14,223,352
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Tomlinson Group Investments
Limited

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s): Gregory Tomlinson has the
power to control the exercise of a
right to vote attached to the
product and the power to control
the acquisition and disposal of
the product. These shares were

acquired pursuant to the Dividend
Reinvestment Plan 2019.
For that relevant interest -
Number held in class before acquisition or disposal: 3,565,104
Number held in class after acquisition or disposal: 3,634,980
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Harrogate Trustee Limited

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 24 February 2020
Nature of transaction: Acquisition of 273,069 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan
2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$320,856.51

Number of financial products to which the transaction
related:
273,069
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 24 February 2020
Nature of transaction: Acquisition of 69,786 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan
2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$81,999.46
Number of financial products to which the transaction
related:
69,786
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
No
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -

Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 28 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 28 February 2020
Date of last disclosure: 26 September 2019

Director or senior manager giving disclosure
Full name(s): Earl Gasparich
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Chief Executive Officer

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Beneficial interest in shares
acquired pursuant to the Dividend
Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 2,058,256
Number held in class after acquisition or disposal: 2,085,249
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Earl Gasparich, Celia Gasparich
and Carla Pearce as trustees of
the Gasparich Family Trust

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A

The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 24 February 2020
Nature of transaction: Acquisition of beneficial interest in
26,993 ordinary shares in
Oceania Healthcare Limited in
accordance with the Dividend
Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$31,717.73
Number of financial products to which the transaction
related:
26,993
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest: (1) Beneficial owner of shares
pursuant to a long term incentive
plan, under which shares are
held by OCA Employees Trustee
Limited
(2) Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee

Share Scheme, under which
shares are held by OCA
Employees Trustee Limited
For that relevant interest -
Number held in class: (1) 696,203
(2) 780
Current registered holder(s): OCA Employees Trustee Limited
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 28 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 28 February 2020
Date of last disclosure: 26 September 2019

Director or senior manager giving disclosure
Full name(s): Matthew Ward
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Chief Financial Officer

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and beneficial owner
of shares acquired pursuant to the
Dividend Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 513,781
Number held in class after acquisition or disposal: 520,519
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Matthew Ward

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s): Beneficial owner of shares
acquired pursuant to the Dividend
Reinvestment Plan 2019
(pursuant to a custodial
arrangement with ASB Nominees
Limited)
For that relevant interest -
Number held in class before acquisition or disposal: 940,693
Number held in class after acquisition or disposal: 953,030
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: ASB Nominees Limited

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 24 February 2020
Nature of transaction: Acquisition of 6,738 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$7,917.36
Number of financial products to which the transaction
related:
6,736
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A

Date of the prior written clearance (if any): N/A

Details of transactions giving rise to acquisition or disposal
Date of transaction: 24 February 2020
Nature of transaction: Acquisition of 12,337 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan
2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$14,496.08
Number of financial products to which the transaction
related:
12,337
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest: (1) Beneficial owner of shares
pursuant to a long term incentive
plan, under which shares are
held by OCA Employees Trustee
Limited
(2) Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee
Share Scheme, under which
shares are held by OCA
Employees Trustee Limited
For that relevant interest -
Number held in class: (1) 569,621
(2) 780
Current registered holder(s): OCA Employees Trustee Limited
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -

The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 28 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 28 February 2020
Date of last disclosure: 5 February 2020

Director or senior manager giving disclosure
Full name(s): Jill Birch
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: General Manager Sales,
Marketing & Village Operations

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s): Registered and beneficial owner
of shares acquired pursuant to the
Dividend Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 1,003,376
Number held in class after acquisition or disposal: 1,016,535
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Jill Birch

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 24 February 2020
Nature of transaction: Acquisition of 13,159 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$15,462.03
Number of financial products to which the transaction
related:
13,159
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest:
(1) Beneficial owner of shares
pursuant to a long term incentive
plan, under which shares are
held by OCA Employees Trustee
Limited
(2) Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee
Share Scheme, under which

shares are held by OCA
Employees Trustee Limited
For that relevant interest -
Number held in class: (1) 411,392
(2) 780
Current registered holder(s): OCA Employees Trustee Limited
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 28 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 28 February 2020
Date of last disclosure: 26 September 2019

Director or senior manager giving disclosure
Full name(s): Anna Thorburn
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: General Counsel & Company
Secretary

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s): Registered and beneficial owner
of shares acquired pursuant to the
Dividend Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 199,564
Number held in class after acquisition or disposal: 202,181
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Anna Thorburn

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 24 February 2020
Nature of transaction: Acquisition of 2,617 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$3,075.28
Number of financial products to which the transaction
related:
2,617
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest:
(1) Beneficial owner of shares
pursuant to a long term incentive
plan, under which shares are
held by OCA Employees Trustee
Limited
(2) Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee
Share Scheme, under which

shares are held by OCA
Employees Trustee Limited
For that relevant interest -
Number held in class: (1) 126,582
(2) 780
Current registered holder(s): OCA Employees Trustee Limited
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature: 28 February 2020
or
Signature of person authorised to sign on behalf of director
or officer:

Date of signature:
Name and title of authorised person: